John Bishop
Net worth: - $ as of 30/05/2024
Career history of John Bishop
Former positions of John Bishop
Companies | Position | Start | End |
---|---|---|---|
LYRA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 26/02/2023 | 19/06/2024 |
FORMA THERAPEUTICS HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 13/06/2021 | 31/01/2023 |
EPIZYME, INC. | Corporate Officer/Principal | 30/04/2017 | 30/04/2021 |
GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | 22/05/2016 | 30/04/2017 |
MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 31/10/2004 | 30/04/2016 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Director/Board Member | 31/07/2000 | 30/09/2004 |
Corporate Officer/Principal | 31/07/2000 | 30/09/2004 | |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Chief Tech/Sci/R&D Officer | 30/06/1994 | 31/07/2000 |
Training of John Bishop
Tufts University | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Northeastern University | Masters Business Admin |
Statistics
International
United States | 11 |
Operational
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 3 |
Director/Board Member | 1 |
Sectoral
Health Technology | 8 |
Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
GENOCEA BIOSCIENCES, INC. | Health Technology |
LYRA THERAPEUTICS, INC. | Health Technology |
Private companies | 5 |
---|---|
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
Forma Therapeutics Holdings, Inc.
Forma Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA. | Health Technology |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- John Bishop
- Experience